Northwest Biotherapeutics Overview
- Founded
-
1996

- Status
-
Public
- Employees
-
20

- Stock Symbol
-
NWBO

- Investments
-
2
- Share Price
-
$0.73
- (As of Tuesday Closing)
Northwest Biotherapeutics General Information
Description
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Contact Information
- 4800 Montgomery Lane
- Suite 800
- Bethesda, MD 20814
- United States
Northwest Biotherapeutics Stock Performance
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.73 | $0.74 | $0.39 - $2.05 | $779M | 1.05B | 3.04M | $0.08 |
Northwest Biotherapeutics Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 767,103 | 671,624 | 1,130,425 | 144,890 |
Revenue | 1,086 | 1,005 | 1,291 | 2,410 |
EBITDA | 63,844 | 184,723 | (520,852) | (17,837) |
Net Income | 56,586 | 179,126 | (529,821) | (20,812) |
Total Assets | 31,098 | 40,160 | 32,899 | 10,643 |
Total Debt | 30,575 | 37,938 | 19,857 | 18,032 |
Northwest Biotherapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Northwest Biotherapeutics Comparisons
Industry
Financing
Details
Northwest Biotherapeutics Competitors (52)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 - | 00000 |
000 000000000000 | Formerly VC-backed | Epalinges, Switzerland | 000 | 00.000 | 00000000 | 00.000 |
00000000 00000000 | Corporation | Boston, MA | 0 | 000 | 000000000 | 000 |
0000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
000000 | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 |
Northwest Biotherapeutics Executive Team (8)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Marnix Bosch Ph.D | Chief Technology Officer | ||
Alton Boynton Ph.D | Chief Scientific Officer & Founder | ||
Les Goldman | Senior Vice President, Business Development | ||
Linda Powers JD | Chief Executive Officer & Chief Financial Officer, Finance |
Northwest Biotherapeutics Signals
Northwest Biotherapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Northwest Biotherapeutics Acquisitions (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000000 | 28-Aug-2020 | 0000000000 | 00.00 | Other Devices and Supplies | 00000 000 |
MithraGen | 01-Jan-2008 | Merger/Acquisition | Biotechnology |
Northwest Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Biotechnology
Subindustry
Rank
Percentile
